HIV-Resistant Gene Modified Stem Cells and Chemotherapy in Treating Patients With Lymphoma With HIV Infection
Public ClinicalTrials.gov record NCT02343666. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Clinical Trial of Gene-Modified Stem Cells to Generate HIV-Resistant Cells in Conjunction With Standard Chemotherapy for Treatment of Lymphoma in Patients With HIV Infection
Study identification
- NCT ID
- NCT02343666
- Recruitment status
- Withdrawn
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Enrollment
- Not listed
Conditions and interventions
Conditions
- Human Immunodeficiency Virus 1 Positive
- Stage I Adult Hodgkin Lymphoma
- Stage I Adult Non-Hodgkin Lymphoma
- Stage II Adult Hodgkin Lymphoma
- Stage II Adult Non-Hodgkin Lymphoma
- Stage III Adult Hodgkin Lymphoma
- Stage III Adult Non-Hodgkin Lymphoma
- Stage IV Adult Hodgkin Lymphoma
- Stage IV Adult Non-Hodgkin Lymphoma
Interventions
- C46/CCR5/P140K Lentiviral Vector-transduced Autologous HSPCs Biological
- Carmustine Drug
- Filgrastim Biological
- Laboratory Biomarker Analysis Other
- O6-Benzylguanine Drug
- Plerixafor Drug
Biological · Drug · Other
Eligibility (public fields only)
- Age range
- 18 Years to 66 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 14, 2016
- Primary completion
- Jul 31, 2020
- Completion
- Not listed
- Last update posted
- Nov 19, 2018
Started 2016
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Fred Hutch/University of Washington Cancer Consortium | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02343666, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 19, 2018 · Synced Jul 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02343666 live on ClinicalTrials.gov.